Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401.

MLA

Kelly, William Kevin, et al. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401.” Journal of Clinical Oncology, vol. 30, no. 13, May 2012, pp. 1534–40. EBSCOhost, https://doi.org/10.1200/JCO.2011.39.4767.

APA

Kelly, W. K., Halabi, S., Carducci, M., George, D., Mahoney, J. F., Stadler, W. M., Morris, M., Kantoff, P., Monk, J. P., Kaplan, E., Vogelzang, N. J., & Small, E. J. (2012). Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. Journal of Clinical Oncology, 30(13), 1534–1540. https://doi.org/10.1200/JCO.2011.39.4767

Chicago

Kelly, William Kevin, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, et al. 2012. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401.” Journal of Clinical Oncology 30 (13): 1534–40. doi:10.1200/JCO.2011.39.4767.